SCHEMBL5269296

SCHEMBL5269296

CC(C)(C)OC(=O)N1CCC(Oc2ncccc2C(F)(F)F)CC1

nearest known ligand 0.57

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 11/20 0.52
HRH3 Q9Y5N1 2/20 0.48
POLB P06746 1/20 0.47
SSTR1 P30872 1/20 0.47
SSTR4 P31391 1/20 0.47
KDM1A O60341 1/20 0.46
RBP4 P02753 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29913053 1.00 GPR119 (0.52) GPR119HRH3POLBSSTR1SSTR4
SCHEMBL2774820 0.86 GPR119 (0.54) GPR119POLB
SCHEMBL21752528 0.85 GPR119 (0.55) GPR119POLB
SCHEMBL5267821 0.85 SCD (0.48) HRH3SSTR1SSTR4RBP4
SCHEMBL29913160 0.85 SSTR4 (0.52) GPR119POLBSSTR1SSTR4
SCHEMBL27158022 0.85 SSTR4 (0.52) GPR119POLBSSTR1SSTR4
SCHEMBL21752524 0.84 SSTR4 (0.49) GPR119HRH3SSTR1SSTR4
SCHEMBL21752523 0.84 SSTR4 (0.49) GPR119HRH3SSTR1SSTR4
SCHEMBL5267601 0.84 POLB (0.55) GPR119POLB
SCHEMBL14335009 0.84 GPR119 (0.54) GPR119POLBKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240262832-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF VANQUA BIO, INC. (US) 2024-08-08 US disclosed
EP-4329881-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF Vanqua Bio, Inc. (US) 2024-03-06 EP disclosed
CN-117642404-A Small molecule modulators of glucocerebrosidase activity and uses thereof 凡况生化公司 2024-03-01 CN disclosed
WO-2022232383-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF VANQUA BIO, INC. (US) 2022-11-03 WO disclosed
EP-1347990-B1 Peptides having inhibiting activity to nitric oxyde production ASTELLAS PHARMA INC (JP) 2007-10-10 EP disclosed
US-7129243-B2 Peptide compounds ASTELLAS PHARMA INC. (JP) 2006-10-31 US disclosed
US-20040097425-A1 Peptide compounds ASTELLAS PHARMA INC. (JP) 2004-05-20 US disclosed
EP-1347990-A2 PEPTIDE MIT INHIBIERENDER AKTIVITÄT ZUR PRODUKTION VON STICKSTOFFMONOXID FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-10-01 EP disclosed
WO-2002055541-A2 PEPTIDES HAVING INHIBITING ACTIVITY ON THE PRODUCTION OF NITRIC OXIDE FUJISAWA PHARMACEUTICAL CO (JP) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097425-A1 Peptide compounds VIP, NOS1, NOS3 GPR119 118/4885HRH3 1050/4885POLB 3702/4885
US-20240262832-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF GBA1, GAA, GBA2 GPR119 101/4885HRH3 4347/4885POLB 1549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.